Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

Declaration of total number of shares and voting rights

15/04/2020
Dowload PDF File (249Ko)

2019 full-year results and update on activities

09/04/2020
Dowload PDF File (351Ko)

Theranexus annouces the success of its phase 2 trial for THN102 in Parkinson's patients

31/03/2020
Dowload PDF File (351Ko)

Declaration of total number of shares and voting rights

04/02/2020
Dowload PDF File (272Ko)

THERANEXUS reports cash position as of December 31, 2019

27/01/2020
Télécharger le PDF (349Ko)

THERANEXUS announces its financial calendar for 2020

20/01/2020
Download PDF File (276Ko)

THERANEXUS announces the clinical results of its phase 1b study demonstrating the extended pharmacological profile of its drug candidate THN201 compared to donepezil

15/01/2020
Download PDF File (381 Ko)